

S & P 500 (/index/s&p_500)	NASDAQ 100 (/index/nasdaq_100)	DJIA (/index/dow_jones)	NIKKEI 225 (/index/nikkei_225)
1.41	2.77	-11.90	30.10
2,791.06 (0.05%)	7,159.56 (0.04%)	25,815.10 (-0.05%)	21,715.10 (0.14%)
Pre-market Official Close	Pre-market Official Close	Pre-market Official Close	Pre-market Official Close
3/5/2019 EST	3/5/2019 EST	3/5/2019 EST	3/5/2019 EST

Cedrus' Head of Life Sciences, Ms. Kimberly Nearing invited to speak at the BIO CEO & Investor Conference in New York City

PRESS RELEASE PR Newswire

Mar. 3, 2019, 08:00 PM

HONG KONG, March 4, 2019 /PRNewswire/ -- Ms. Kimberly Nearing, Managing Director - Life Sciences at Cedrus Investments ("Cedrus"), served on the **Conference Advisory Committee** and as a speaker on a panel at the 21st annual BIO CEO & Investor Conference in New York City on February 11th and 12th.

BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Each year the BIO CEO & Investor Conference provides a neutral forum where leading institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.

As a member of the Advisory Committee, Ms. Nearing invited **Jinzi Wu, Ph.D., Founder, Chairman and CEO, Ascletis Pharma Inc.** to be a keynote speaker. Ascletis is the first pre-revenue biotechnology company to go public on the Hong Kong Stock Exchange.

The panel Ms. Nearing participated on focused on the impact of the Committee on Foreign Investment in the United States ("CFIUS") on cross-border investments and deal making. Fellow panelists included Jeff Farra, Vice President, Government Affairs, **National Venture Capital Association (NVCA)**; Joseph Benkert, Senior Advisor, **Morrison & Foerster LLP**; and Jun Bao, Ph.D., MBA, President and CEO, **IMPACT Therapeutics**. One of the key take aways from the discussion is that regulatory reform is causing concern and pause on the part of many China-based investors and uncertainty by both investors and early-stage biotech's in the US that relies on these funds. It's unlikely these investments would stop altogether, it is very possible that these investments will go to other countries (including Europe) and or other industries.

Nareg Sagherian, Director, Biotechnology Innovation Organization said, "BIO's conference audience greatly benefited from Kim's experienced perspective on the priorities of life sciences investors in China and her ability to summarize current concerns among deal makers interested in cross-border investing. Cedrus has an impressive network of contacts in China and she was very helpful to us in putting our program together."

About Cedrus Investments

Cedrus Investments is a global boutique investment firm headquartered in Hong Kong, specializing in Asset Management and Financial Advisory Services. Cedrus has extensive experience and a global network in the life sciences industry together with cross-border transactions track record in geographies, including China, Australia, Asia, U.S., and Europe.

Media Enquiry:

Cedrus Investments Ltd.

Amy Sin

+852-3519-2828

information@cedrusinvestments.com

Logo - <https://photos.prnasia.com/prnh/20150930/8521506461LOGO>

SOURCE Cedrus Investments